Patients with type 2 diabetes who were treated with weekly injections of the drug Semaglutide were able to achieve an average weight loss of nearly 10kg, according to a new study published in The Lancet today.
Led by Melanie Davies, Professor of Diabetes Medicine at the University of Leicester and Co-Director of the Leicester Diabetes Center, the study showed that two-thirds of type 2 diabetes patients were treated by injection weekly dose of 2.4mg of Semaglutide was able to lose at least 5% of their body weight and achieved a significant improvement in blood glucose control.
More than a quarter of patients were able to lose more than 15% of their body weight – far above what was seen with any other medication given to people with diabetes.
These results are encouraging and represent a new era in weight management in people with type 2 diabetes – they mark a real paradigm shift in our ability to treat obesity, the results bring us closer to what we see with more aggressive surgery. It is also encouraging that we have seen real improvements in overall health, along with weight loss, with significant improvements in physical activity scores, blood pressure and blood glucose control. “
Melanie Davies, Professor, Diabetes Medicine, University of Leicester, Associate Director, Leicester Diabetes Center
This global multicenter trial was conducted at 149 sites in 12 countries across North America, Europe, South America, the Middle East, South Africa and Asia, involving 1,210 patients with the disease. type 2 diabetes where current treatment did not achieve adequate control of blood sugar, for example through diet and exercise, or through the use of metformin and other glucose-lowering medications used to control the disease.
It is one of a package of studies conducted as part of the Semaglutide Treatment Impact Program for People with Obesity Program (STEP). Professor Davies has been involved in the four STEP clinical trials involving Semaglutide for weight management completed to date, where the medication has been shown to help patients get average weight loss between 10kg and 17kg body weight.
Being obese or obese contributes significantly to type 2 diabetes. Many patients can manage their type 2 diabetes by eating a healthy diet, exercising regularly, and ‘use of medications to control blood sugar, or achieve glycemic control but for a significant minority of patients who have seen little improvement despite these methods, semiglutide is a promising improvement.
The LDC has a world-renowned multidisciplinary research team, leading the way and providing the evidence behind the Leicester Diabetes Centre’s education programs and expanding the knowledge base for health and social care management. disease.